Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMLEX1D)

Drug Name
Lexibulin Drug Info
Synonyms
Lexibulin; CYT-997; Microtubule inhibitor (oral, solid tumors) Cytopia; VDA anticancer program (iv), Cytopia; Lexibulin (iv infusion, cancer), YM BioSciences; Lexibulin (oral capsule, cancer), YM Biosciences; CYT-997 (iv infusion, cancer), Cytopia; CYT-997 (iv infusion, cancer), YM BioSciences; CYT-997 (oral capsule, cancer), Cytopia; CYT-997 (oral capsule, cancer), YM Biosciences; Vascular disrupting agent/ tubulin inhibitor (iv, cancer), Cytopia; Vascular disrupting agent/tubulin inhibitor (oral, cancer), Cytopia; Vascular targeting agent/ tubulin inhibitor (iv, cancer), Cytopia
Cross-matching ID
PubChem CID
11351021
TTD Drug ID
D01JNE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Focal adhesion 2.27 0.00e+0 180/201 (89.55%) ACTN1;THBS1;ACTN4;...
Regulation of actin cytoskeleton 2.10 0.00e+0 185/218 (84.86%) ACTN1;ACTN4;ITGA6;...
ECM-receptor interaction 2.05 0.00e+0 80/88 (90.91%) THBS1;ITGA6;LAMC2;...
Proteoglycans in cancer 2.00 0.00e+0 172/205 (83.9%) THBS1;PLAU;PLAUR;...
Hypertrophic cardiomyopathy 2.00 0.00e+0 81/90 (90%) TPM1;ITGA6;TPM4;...
Dilated cardiomyopathy 1.90 9.75e-3 86/96 (89.58%) TPM1;ITGA6;TPM4;...
Amoebiasis 1.89 8.35e-3 99/102 (97.06%) ACTN1;ACTN4;LAMC2;...
Salmonella infection 1.89 7.31e-3 198/249 (79.52%) PODXL;FLNA;BIRC2;...
AGE-RAGE signaling pathway in diabetic complications 1.87 7.80e-3 97/100 (97%) CCND1;F3;JUN;...
Bacterial invasion of epithelial cells 1.86 9.36e-3 59/77 (76.62%) ILK;CAV1;CAV2;...
Chagas disease 1.85 8.51e-3 93/102 (91.18%) IRAK1;JUN;TGFB2;...
Hippo signaling pathway 1.85 7.80e-3 120/186 (64.52%) AREG;CCN2;CCND1;...
Arrhythmogenic right ventricular cardiomyopathy 1.85 7.20e-3 70/77 (90.91%) ITGA6;ITGA5;ITGA3;...
PI3K-Akt signaling pathway 1.80 1.17e-2 317/354 (89.55%) AREG;THBS1;ITGA6;...
Pathogenic Escherichia coli infection 1.79 1.40e-2 152/197 (77.16%) IRAK1;JUN;MYH9;...
Glycosaminoglycan biosynthesis 1.77 1.61e-2 40/58 (68.97%) EXT1;CSGALNACT1;CHST11;...
NF-kappa B signaling pathway 1.75 1.93e-2 90/104 (86.54%) PLAU;RELB;PTGS2;...
Small cell lung cancer 1.74 1.82e-2 90/92 (97.83%) ITGA6;CCND1;LAMC2;...
Apelin signaling pathway 1.74 1.79e-2 117/137 (85.4%) CCN2;CCND1;SPHK1;...
Rap1 signaling pathway 1.74 1.87e-2 184/210 (87.62%) THBS1;PDGFC;EPHA2;...
Tight junction 1.72 2.17e-2 130/169 (76.92%) ACTN1;ACTN4;CCND1;...
TNF signaling pathway 1.72 2.13e-2 103/112 (91.96%) PTGS2;BIRC2;JUN;...
Phospholipase D signaling pathway 1.71 2.09e-2 134/148 (90.54%) PDGFC;SPHK1;PRKCA;...
Adherens junction 1.70 2.49e-2 63/71 (88.73%) ACTN1;ACTN4;EGFR;...
Yersinia infection 1.66 3.42e-2 120/137 (87.59%) ITGA5;IRAK1;JUN;...
Leukocyte transendothelial migration 1.66 3.42e-2 90/114 (78.95%) ACTN1;ACTN4;PRKCA;...
Relaxin signaling pathway 1.65 3.47e-2 114/129 (88.37%) JUN;COL4A5;PRKCA;...
Colorectal cancer 1.65 3.38e-2 84/86 (97.67%) AREG;CCND1;EREG;...
VEGF signaling pathway 1.64 3.47e-2 50/59 (84.75%) PTGS2;SPHK1;PRKCA;...
Epithelial cell signaling in Helicobacter pylori infect... 1.64 3.43e-2 62/70 (88.57%) HBEGF;JUN;EGFR;...
Fatty acid degradation -1.61 3.00e-2 40/43 (93.02%) CPT1A;ACADVL;ADH1A;...
Peroxisome -1.62 2.76e-2 72/82 (87.8%) PHYH;EHHADH;ECH1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.63 2.63e-2 20/26 (76.92%) GPLD1;PIGQ;PIGG;...
Drug metabolism -1.63 2.66e-2 78/151 (51.66%) GSTT1;IMPDH2;CYP2C9;...
Sulfur metabolism -1.64 2.64e-2 9/10 (90%) TST;SUOX;SELENBP1
Arachidonic acid metabolism -1.67 2.16e-2 48/61 (78.69%) GGT1;GPX3;PLA2G4A;...
Ascorbate and aldarate metabolism -1.67 2.18e-2 15/30 (50%) UGDH;UGT2A3;ALDH3A2;...
Glycolysis / Gluconeogenesis -1.68 2.24e-2 56/67 (83.58%) ADH1B;HK2;PGM1;...
Glyoxylate and dicarboxylate metabolism -1.72 1.75e-2 23/30 (76.67%) MDH2;GLDC;AMT;...
Proximal tubule bicarbonate reclamation -1.73 1.56e-2 21/23 (91.3%) ATP1A2;GLUD1;SLC4A4;...
Ribosome -1.73 1.59e-2 113/158 (71.52%) RPL23A;RPLP1;RPS18;...
One carbon pool by folate -1.73 1.63e-2 15/20 (75%) AMT;MTHFS;MTHFD1;...
Folate biosynthesis -1.74 1.54e-2 23/26 (88.46%) AKR1B1;DHFR;GCH1;...
Nitrogen metabolism -1.83 4.33e-3 16/17 (94.12%) CA3;GLUD1;GLUD2;...
Alanine, aspartate and glutamate metabolism -1.83 4.60e-3 27/37 (72.97%) GOT1;GLUD1;GAD2;...
Oxidative phosphorylation -1.84 3.27e-3 93/133 (69.92%) ATP6V0E2;ATP5F1B;ATP5F1A;...
Steroid hormone biosynthesis -1.86 2.33e-3 43/61 (70.49%) HSD17B7;UGT2A3;HSD17B8;...
Glutathione metabolism -1.86 2.51e-3 43/57 (75.44%) GSTK1;RRM1;PRDX6;...
Graft-versus-host disease -1.88 2.04e-3 32/42 (76.19%) HLA-DOB;HLA-DRA;HLA-DMB;...
Tryptophan metabolism -1.88 2.23e-3 35/42 (83.33%) ALDH8A1;KYNU;ECHS1;...
Pentose and glucuronate interconversions -1.93 1.63e-3 17/34 (50%) UGDH;UGT2A3;AKR1B1;...
Histidine metabolism -1.93 1.82e-3 16/22 (72.73%) ALDH3A2;HNMT;ALDH9A1;...
Type I diabetes mellitus -1.94 2.04e-3 38/43 (88.37%) HLA-DOB;GAD2;HLA-DRA;...
Autoimmune thyroid disease -1.99 2.33e-3 46/53 (86.79%) HLA-DOB;HLA-DRA;HLA-DMB;...
Antigen processing and presentation -2.00 2.72e-3 60/78 (76.92%) HLA-DOB;HLA-DRA;HLA-DMB;...
Metabolism of xenobiotics by cytochrome P450 -2.02 1.63e-3 49/77 (63.64%) CBR1;MGST2;GSTM4;...
Allograft rejection -2.07 2.04e-3 32/38 (84.21%) HLA-DOB;HLA-DRA;HLA-DMB;...
Glycine, serine and threonine metabolism -2.11 0.00e+0 31/40 (77.5%) GAMT;BHMT;GATM;...
Mismatch repair -2.12 0.00e+0 22/23 (95.65%) SSBP1;POLD3;MSH2;...
DNA replication -2.20 0.00e+0 34/36 (94.44%) MCM7;POLE2;SSBP1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 1.11uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 1.11uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 1.11uM 6H
MDST8 CVCL_1400 Homo sapiens 1.11uM 6H
NCI-H508 CVCL_1561 Homo sapiens 1.11uM 6H
SNU-1040 CVCL_5001 Homo sapiens 1.11uM 6H
SNU-C4 CVCL_5008 Homo sapiens 1.11uM 6H
SNU-C5 CVCL_5009 Homo sapiens 1.11uM 6H
SW480 CVCL_0546 Homo sapiens 1.11uM 6H
SW620 CVCL_0547 Homo sapiens 1.11uM 6H
SW948 CVCL_0550 Homo sapiens 1.11uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 1.11uM 6H
HT115 CVCL_1294 Homo sapiens 1.11uM 6H
RKO CVCL_0504 Homo sapiens 1.11uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM 6H
SNG-M CVCL_1707 Homo sapiens 1.11uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 1.11uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.11uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 1.11uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 1.11uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 1.11uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 1.11uM 6H
T3M-10 CVCL_1729 Homo sapiens 1.11uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 1.11uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 1.11uM 6H
HCC515 CVCL_5134 Homo sapiens 1.11uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 1.11uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 1.11uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 1.11uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 1.11uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 1.11uM 6H
OV7 CVCL_1623 Homo sapiens 1.11uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 1.11uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMUG-S CVCL_1666 Homo sapiens 1.11uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 1.11uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 1.11uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 1.11uM 6H
PL-21 CVCL_2161 Homo sapiens 1.11uM 6H
SKM-1 CVCL_0010 Homo sapiens 1.11uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 1.11uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.11uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 1.11uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 1.11uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 1.11uM 6H